A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 536 participants.

Also called NCT03338010

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 536 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03338010
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03338010. Randomized; no masking; primary purpose treatment. Start 2018-03-22 (actual); primary completion 2020-03-18 (actual). Results posted on 2021-05-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
Intervention (Drug)
LY2963016
Intervention (Drug)
Lantus®
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03338010
Content hash
547582e0d661413156327395052427a99ea9921abea12d82ca94fb990ebe25bf